Financial Gravity Wealth Inc. acquired a new stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 567 shares of the biopharmaceutical company’s stock, valued at approximately $232,000.
Other institutional investors have also recently bought and sold shares of the company. Capital Financial Planning LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $33,000. Landsberg Bennett & Dubbaneh LLC boosted its position in shares of Regeneron Pharmaceuticals by 13.5% in the 1st quarter. Landsberg Bennett & Dubbaneh LLC now owns 815 shares of the biopharmaceutical company’s stock worth $332,000 after purchasing an additional 97 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of Regeneron Pharmaceuticals by 1.5% in the 3rd quarter. Nordea Investment Management AB now owns 4,215 shares of the biopharmaceutical company’s stock worth $1,703,000 after purchasing an additional 64 shares in the last quarter. Morgan Stanley boosted its position in shares of Regeneron Pharmaceuticals by 70.6% in the 3rd quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock worth $187,719,000 after purchasing an additional 192,236 shares in the last quarter. Finally, Meeder Asset Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 59.8% in the 4th quarter. Meeder Asset Management Inc. now owns 12,975 shares of the biopharmaceutical company’s stock worth $4,846,000 after purchasing an additional 4,858 shares in the last quarter. 66.97% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently commented on REGN shares. Guggenheim cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $466.00 to $425.00 in a research report on Friday, February 22nd. TheStreet raised Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, January 17th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price target on the stock in a research report on Thursday, February 7th. BidaskClub cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 7th. Finally, Cowen reissued a “hold” rating and issued a $385.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, January 7th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $413.94.
REGN stock opened at $333.34 on Friday. The company has a market capitalization of $36.43 billion, a P/E ratio of 16.92, a price-to-earnings-growth ratio of 1.29 and a beta of 1.18. Regeneron Pharmaceuticals Inc has a 12-month low of $281.89 and a 12-month high of $442.00. The company has a current ratio of 4.47, a quick ratio of 3.67 and a debt-to-equity ratio of 0.08.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $1.74. The business had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.73 billion. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The firm’s quarterly revenue was up 21.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.23 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals Inc will post 19.92 EPS for the current year.
In related news, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 12.42% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “567 Shares in Regeneron Pharmaceuticals Inc (REGN) Acquired by Financial Gravity Wealth Inc.” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2019/04/21/567-shares-in-regeneron-pharmaceuticals-inc-regn-acquired-by-financial-gravity-wealth-inc.html.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Recommended Story: What is Green Investing?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.